How Risky Is Pfizer’s Launch Of Its Remicade Biosimilar?

Oct 19 2016

• By Brenda Sandburg

Listen to this article

Following Sandoz’s Zarxio playbook, Pfizer plans to market Inflectra while patent litigation continues; February 2017 trial on cell culture media patent could answer question of potential damages.

Celltrion Inc. and partner Pfizer Inc. knocked out one of Janssen Biotech Inc.’s Remicade (infliximab) patents in district court and are betting they will win a ruling of non-infringement of a cell culture media patent. But even if they don’t prevail, they may rake in far more in revenues from an Inflectra biosimilar launch than would pay out in potential damages.

Pfizer announced on Oct. 17 that it would begin shipping Inflectra (infliximab-dyyb), its biosimilar to Janssen’s tumor necrosis factor inhibitor,...

More from Biosimilars

GB-Free-Tracker-The Secret to Walking More: It’s Not Counting Steps
Nov 02 2025
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
Regeneron’s Linvoseltamab CRL Underlines Risks Of Third-Party Manufacturers
Aug 26 2024
• By Bridget Silverman
The bispecific antibody is the latest example of a growing number of biologics receiving complete response letters related to third-party manufacturing facilities.
Facility Deficiencies Drive Rising CRL Rates For CDER Biologics
Aug 26 2024
• By Bridget Silverman
A US FDA analysis found that facility inspection issues were the fastest growing factor in the recent rise of complete response letters for biologics licensing applications, in part reflecting the limitations of single-product inspections at contract facilities manufacturing multiple products.
EU Biosimilar Filings, Opinions And Approvals
Aug 05 2024
• By Ian Schofield
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.

More from Biosimilars & Generics

Facility Deficiencies Drive Rising CRL Rates For CDER Biologics
Aug 26 2024
• By Bridget Silverman
A US FDA analysis found that facility inspection issues were the fastest growing factor in the recent rise of complete response letters for biologics licensing applications, in part reflecting the limitations of single-product inspections at contract facilities manufacturing multiple products.
Novartis Takes Fight To The FDA After US Entresto Generic Approval
Aug 12 2024
• By Dean Rudge
Novartis continues to fight tooth and nail to protect its $3bn Entresto brand in the US following the latest FDA approval of a generic version.
EU Biosimilar Filings, Opinions And Approvals
Aug 05 2024
• By Ian Schofield
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.